Arcus Biosciences Inc (NYSE: RCUS) kicked off on Monday, up 7.45% from the previous trading day, before settling in for the closing price of $17.31. Over the past 52 weeks, RCUS has traded in a range of $6.50-$18.98.
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -10.20%. While this was happening, its average annual earnings per share was recorded -17.15%. With a float of $65.32 million, this company’s outstanding shares have now reached $106.40 million.
Arcus Biosciences Inc (RCUS) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Arcus Biosciences Inc is 38.63%, while institutional ownership is 62.48%. The most recent insider transaction that took place on Oct 08 ’25, was worth 568,611. In this transaction Chief Operating Officer of this company sold 37,792 shares at a rate of $15.05, taking the stock ownership to the 214,232 shares. Before that another transaction happened on Oct 06 ’25, when Company’s Chief Operating Officer sold 12,500 for $14.54, making the entire transaction worth $181,801. This insider now owns 214,232 shares in total.
Arcus Biosciences Inc (RCUS) Latest Financial update
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -1 earnings per share (EPS), higher than consensus estimate (set at -1.07) by 0.07. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.22 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -17.15% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -2.73% during the next five years compared to -10.20% drop over the previous five years of trading.
Arcus Biosciences Inc (NYSE: RCUS) Trading Performance Indicators
Take a look at Arcus Biosciences Inc’s (RCUS) current performance indicators. Last quarter, stock had a quick ratio of 4.50. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.56.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.17, a number that is poised to hit -1.31 in the next quarter and is forecasted to reach -4.21 in one year’s time.
Technical Analysis of Arcus Biosciences Inc (RCUS)
The latest stats from [Arcus Biosciences Inc, RCUS] show that its last 5-days average volume of 1.22 million was superior to 1.02 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 69.58%.
During the past 100 days, Arcus Biosciences Inc’s (RCUS) raw stochastic average was set at 98.25%, which indicates a significant increase from 95.88% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.18 in the past 14 days, which was higher than the 0.64 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $13.16, while its 200-day Moving Average is $10.58. Now, the first resistance to watch is $19.11. This is followed by the second major resistance level at $19.62. The third major resistance level sits at $20.45. If the price goes on to break the first support level at $17.77, it is likely to go to the next support level at $16.94. The third support level lies at $16.43 if the price breaches the second support level.
Arcus Biosciences Inc (NYSE: RCUS) Key Stats
The company with the Market Capitalisation of 1.98 billion has total of 106,431K Shares Outstanding. Its annual sales at the moment are 258,000 K in contrast with the sum of -283,000 K annual income. Company’s last quarter sales were recorded 160,000 K and last quarter income was 0 K.
